![Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]](https://joelgalvan.site/wp-content/uploads/2025/02/globe-newswire.svg.svg+xml){kind=small}
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing…
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing…